Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$654K Hold
2,599
0.47% 38
2026
Q1
$565K Hold
2,599
0.38% 39
2025
Q4
$594K Hold
2,599
0.44% 37
2025
Q3
$602K Hold
2,599
0.49% 38
2025
Q2
$482K Hold
2,599
0.44% 42
2025
Q1
$545K Buy
+2,599
New +$505K 0.54% 39
2024
Q3
$513K Hold
2,599
0.48% 40
2024
Q2
$446K Hold
2,599
0.43% 43
2024
Q1
$473K Hold
2,599
0.44% 42
2023
Q4
$403K Hold
2,599
0.41% 41
2023
Q3
$387K Hold
2,599
0.42% 43
2023
Q2
$350K Hold
2,599
0.37% 46
2023
Q1
$414K Hold
2,599
0.42% 44
2022
Q4
$420K Hold
2,599
0.47% 44
2022
Q3
$349K Buy
+2,599
New +$373K 0.42% 49
2022
Q1
$387K Hold
2,829
0.39% 51
2021
Q4
$383K Hold
2,829
0.38% 51
2021
Q3
$305K Sell
2,829
-490
-15% -$56K 0.32% 59
2021
Q2
$374K Buy
3,319
+743
+29% +$83.7K 0.37% 54
2021
Q1
$279K Hold
2,576
0.31% 55
2020
Q4
$276K Hold
2,576
0.33% 57
2020
Q3
$226K Hold
2,576
0.31% 57
2020
Q2
$253K Buy
+2,576
New +$227K 0.34% 52
2020
Q1
Sell
-2,404
Closed -$213K 59
2019
Q4
$213K Buy
+2,404
New +$200K 0.2% 59
2019
Q1
Sell
-2,279
Closed -$210K 60
2018
Q4
$210K Hold
2,279
0.18% 54
2018
Q3
$216K Hold
2,279
0.16% 56
2018
Q2
$211K Buy
2,279
+58
+3% +$5.66K 0.16% 57
2018
Q1
$210K Buy
+2,221
New +$244K 0.16% 54

Other funds holding ABBV

Lesa Sroufe & Co's ABBV Position: Q2 2026 in Review

Lesa Sroufe & Co held its AbbVie (ABBV) position steady in Q2 2026 at 2,599 shares worth $654K. The position accounts for 0.47% of the portfolio, ranked #38.

Lesa Sroufe & Co first reported a position in ABBV in Q1 2018 and has held it in 28 quarters since. 2,007 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Lesa Sroufe & Co held 2,599 shares of AbbVie worth $654K as of Q2 2026.
  • Lesa Sroufe & Co left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.47% of Lesa Sroufe & Co's portfolio in Q2 2026, its #38 holding.
  • Lesa Sroufe & Co first reported a position in AbbVie in Q1 2018 and has held it in 28 quarters since.
  • 2,007 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lesa Sroufe & Co's 13F filing for Q2 2026, filed 22 Jul 2026.